CHRONIC KIDNEY DISEASE MANAGEMENT IN PRIMARY CARE HANDBOOK REFRESHED FOR HCPs
Breonny Robson, GM Clinical and Research
Kidney Health Australia
Dr Chris Bollen GP, Oakden Medical Centre &
PEAK Committee Member, Kidney Health Australia
Professor Shilpa Jesudason, Nephrologist
Professor of Medicine, University of Adelaide,
Director of Dialysis, Royal Adelaide Hospital &
PEAK Committee Member, Kidney Health Australia
Chris Picton MP, Minister for Health and Wellbeing
Government of South Australia
Kidney Health Australia’s latest kidney disease guide for primary care practitioners is expected to be pivotal in slowing down the rates of kidney failure, which have doubled in the past 20 years and if left unchecked will grow by a further 42% by 2030, according to the health charity.
With specific reference to new kidney treatments and culturally safe kidney care for First Nations Australians, the 5th edition of Chronic Kidney Disease (CKD) Management in Primary Care handbook, known as the ‘kidney bible’, is a significant step-up in enabling earlier diagnosis of kidney disease for GPs and other front-line healthcare professionals.
The number of Australians treated for kidney failure has doubled in the last two decades, causing widespread treatment shortages, increasing costs, and plunging thousands of Australians into highly invasive and life-altering dialysis. With 1.8 million people currently unaware they have kidney disease, this number will only continue to grow.
Breonny Robson, General Manager, Clinical and Research at Kidney Health Australia, said: “The new edition of the GP handbook helps health professionals working in primary care to identify people at risk of CKD in their practice and proactively diagnose CKD. It outlines key strategies to slow the progression of CKD and reduce cardiovascular risk, including simple colour-coded action plans for different stages of the disease.”
Ms Robson added, “It’s an exciting time in CKD care, with new treatments now available that have been shown to slow the progression of CKD to kidney failure by 15 years or more. The handbook contains significant new information on using these medications in people with CKD so that their health outcomes and quality of life can be extended for many years to come.”
The handbook is endorsed by Australian and New Zealand Society of Nephrology (ANZSN), the Renal Society of Australasia (RSA) and the Australian Primary Healthcare Nurses Association (APNA) and Australian College of Rural and Remote Medicine (ACRRM). It has been approved as an Acceptable Clinical Resource by the Royal Australian College of General Practitioners (RACGP).
South Australian Minister of Health and Wellbeing Chris Picton launched the handbook at an event on World Kidney Day, 14th March, at Royal Adelaide Hospital.
The handbook is available from Kidney Health Australia in hardcopy or free download here https://kidney.org.au/health-professionals/ckd-management-handbook
-
Analogy of the system, rather than the ED front door
“The problem of blockages shows up in ambulance ramping and long wait times, but this is a complex issue requiring whole-of-health system solutions,” according to Professor Hugh Grantham, Chair of Emergency Medicine Foundation in an interview with Australian Health Journal.
-
Reflecting on a pivotal year for pharmacy
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
